| Literature DB >> 36101832 |
A H Ayesha Lavell1,2, Jonne J Sikkens1,2, Arthur W D Edridge2,3, Karlijn van der Straten2,3,4, Ferdyansyah Sechan2,3, Melissa Oomen2,3, David T P Buis1,2, Michiel Schinkel2,5, Judith A Burger2,3, Meliawati Poniman2,3, Jacqueline van Rijswijk2,3, Menno D de Jong2,3, Godelieve J de Bree2,4, Edgar J G Peters1,2, Yvo M Smulders1,2, Rogier W Sanders2,3,6, Marit J van Gils2,3, Lia van der Hoek2,3, Marije K Bomers1,2.
Abstract
Antibodies against seasonal human coronaviruses (HCoVs) are known to cross-react with SARS-CoV-2, but data on cross-protective effects of prior HCoV infections are conflicting. In a prospective cohort of healthcare workers (HCWs), we studied the association between seasonal HCoV (OC43, HKU1, 229E and NL63) nucleocapsid protein IgG and SARS-CoV-2 infection during the first pandemic wave in the Netherlands (March 2020 - June 2020), by 4-weekly serum sampling. HCW with HCoV-OC43 antibody levels in the highest quartile, were less likely to become SARS-CoV-2 seropositive when compared with those with lower levels (6/32, 18.8%, versus 42/97, 43.3%, respectively: p = 0.019; HR 0.37, 95% CI 0.16-0.88). We found no significant association with HCoV-OC43 spike protein IgG, or with antibodies against other HCoVs. Our results indicate that the high levels of HCoV-OC43-nucleocapsid antibodies, as an indicator of a recent infection, are associated with protection against SARS-CoV-2 infection; this supports and informs efforts to develop pancoronavirus vaccines.Entities:
Keywords: Immunology; Molecular physiology; Virology
Year: 2022 PMID： 36101832 PMCID： PMC9458542 DOI： 10.1016/j.isci.2022.105105
Source DB: PubMed Journal: iScience ISSN： 2589-0042